18F-fluorodeoxyglucose and 18F-sodium fluoride for imaging atherosclerotic plaque activity

Kwieciński, Jacek

doi:10.1007/s12350-022-02947-0

Cited by 1 publication

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is challenging to diagnose the non-calcified plaque with computed tomography (CT) because soft tissues are not sensitive to X-ray attenuation (Zhang et al, 2021). Positron emission tomography (PET) with 18F-FDG has been proposed as a noninvasive gold standard to identify the vulnerability of plaque (Kwiecinski, 2022), since the tracer-uptake was strongly connected with macrophage infiltration (Joshi et al, 2014). However, excessive myocardial metabolic uptake frequently resulted in erroneous signals (Chen and Dilsizian, 2013).…”

Section: Pet/ctmentioning

confidence: 99%

Advances of nanoparticle-mediated diagnostic and theranostic strategies for atherosclerosis

Lin,

Chen,

Yan

et al. 2023

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Atherosclerotic plaque remains the primary cause of morbidity and mortality worldwide. Accurate assessment of the degree of atherosclerotic plaque is critical for predicting the risk of atherosclerotic plaque and monitoring the results after intervention. Compared with traditional technology, the imaging technologies of nanoparticles have distinct advantages and great development prospects in the identification and characterization of vulnerable atherosclerotic plaque. Here, we systematically summarize the latest advances of targeted nanoparticle approaches in the diagnosis of atherosclerotic plaque, including multimodal imaging, fluorescence imaging, photoacoustic imaging, exosome diagnosis, and highlighted the theranostic progress as a new therapeutic strategy. Finally, we discuss the major challenges that need to be addressed for future development and clinical transformation.

show abstract